Trends and impact on cold ischemia time and clinical outcomes using virtual crossmatch for deceased donor kidney transplantation in the United States.


Journal

Kidney international
ISSN: 1523-1755
Titre abrégé: Kidney Int
Pays: United States
ID NLM: 0323470

Informations de publication

Date de publication:
09 2021
Historique:
received: 17 01 2021
revised: 26 02 2021
accepted: 01 04 2021
pubmed: 4 5 2021
medline: 26 8 2021
entrez: 3 5 2021
Statut: ppublish

Résumé

For assessing human leukocyte antigen compatibility in deceased donor kidney transplantation, virtual crossmatch is used as an alternative to physical crossmatch and has potential to reduce cold ischemia time. The 2014 United States kidney allocation system prioritized highly sensitized candidates but led to increased shipping of kidneys. Using data from the Scientific Registry of Transplant Recipients, we evaluated changes in virtual crossmatch use with the new allocation policy and the impact of virtual crossmatch use on cold ischemia time and transplant outcomes. This was a retrospective cohort study of adult deceased donor kidney recipients in the United States (2011-2018) transplanted with either 9,632 virtual or 71,839 physical crossmatches. Before allocation change, only 9% of transplants were performed relying on a virtual crossmatch. After the 2014 allocation change, this increased by 2.4%/year so that 18% transplants in 2018 were performed with just a virtual crossmatch. There was significant variation in virtual crossmatch use among transplant regions (range 0.7-36%) and higher use was noted among large volume centers. Compared to physical crossmatches, virtual crossmatches were significantly associated with shorter cold ischemia times (mean 15.0 vs 16.5 hours) and similar death-censored graft loss and mortality (both hazard ratios HR 0.99) at a median follow-up of 2.9 years. Thus, our results show that virtual crossmatch is an attractive strategy for shortening cold ischemia time without negatively impacting transplant outcomes. Hence, strategies to optimize use and reduce practice variation may allow for maximizing benefits from virtual crossmatch.

Identifiants

pubmed: 33940109
pii: S0085-2538(21)00460-9
doi: 10.1016/j.kint.2021.04.020
pmc: PMC8384718
mid: NIHMS1701244
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

660-671

Subventions

Organisme : NIDDK NIH HHS
ID : K08 DK119576
Pays : United States

Informations de copyright

Copyright © 2021 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Références

Curr Opin Nephrol Hypertens. 2010 Nov;19(6):598-602
pubmed: 20720491
Am J Transplant. 2014 Sep;14(9):1964-75
pubmed: 25088978
Am J Transplant. 2016 May;16(5):1503-15
pubmed: 26602886
Kidney Int. 2015 Feb;87(2):343-9
pubmed: 25229341
Acad Pediatr. 2013 Nov-Dec;13(6 Suppl):S38-44
pubmed: 24268083
Transplantation. 2010 Jan 27;89(2):185-93
pubmed: 20098281
Kidney Int. 2020 Apr;97(4):659-662
pubmed: 32200862
Hum Immunol. 2017 Jan;78(1):16-18
pubmed: 27743878
Transplantation. 2020 Jun;104(6):1239-1245
pubmed: 31449187
Kidney Int. 2020 Apr;97(4):657-659
pubmed: 32200861
Am J Transplant. 2016 Jun;16(6):1834-47
pubmed: 26932731
Am J Transplant. 2006 Oct;6(10):2307-15
pubmed: 16939516
Transplantation. 2016 Feb;100(2):422-8
pubmed: 26262505
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2060-2062
pubmed: 29162592
Hum Immunol. 2017 Jan;78(1):30-36
pubmed: 27773831
Am J Transplant. 2017 Aug;17(8):2139-2143
pubmed: 28168823
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2063-2065
pubmed: 29162594
Nephrol Dial Transplant. 2009 Mar;24(3):1039-47
pubmed: 19103734
Clin J Am Soc Nephrol. 2016 Feb 5;11(2):324-31
pubmed: 26668026
Hum Immunol. 2018 Oct;79(10):711-715
pubmed: 30081064
Clin J Am Soc Nephrol. 2008 Sep;3(5):1227-31
pubmed: 18701611
Transplantation. 2016 May;100(5):1103-10
pubmed: 26950720
Kidney Int. 2020 Apr;97(4):662-663
pubmed: 32200863
Hum Immunol. 2018 Jan;79(1):28-38
pubmed: 29109009
Am J Transplant. 2009 Aug;9(8):1886-93
pubmed: 19563341
J Am Soc Nephrol. 2020 Dec;31(12):2900-2911
pubmed: 33037131
J Am Coll Surg. 2020 Apr;230(4):373-379
pubmed: 32035182
N Engl J Med. 1969 Apr 3;280(14):735-9
pubmed: 4886455
Hum Immunol. 2017 Jan;78(1):19-23
pubmed: 27840088
Am J Transplant. 2007 Mar;7(3):626-32
pubmed: 17352712
HLA. 2019 Dec;94(6):471-481
pubmed: 31515937
Transplant Proc. 2014 Sep;46(7):2195-8
pubmed: 25242749
Transplantation. 2008 Dec 27;86(12):1864-8
pubmed: 19104435
Am Surg. 2021 Jan;87(1):109-113
pubmed: 32833493

Auteurs

Chethan M Puttarajappa (CM)

Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Electronic address: puttarajappacm@upmc.edu.

Dana Jorgensen (D)

Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Jonathan G Yabes (JG)

Center for Research on Healthcare Data, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Kwonho Jeong (K)

Center for Research on Healthcare Data, Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Adriana Zeevi (A)

Department of Pathology, University of Pittsburgh, Pittsburgh, USA.

John Lunz (J)

Transplant Immunology Laboratory, LifeLink Foundation, Tampa, Florida, USA.

Amit D Tevar (AD)

Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Michele Molinari (M)

Department of Surgery, Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Sumit Mohan (S)

Department of Medicine, Division of Nephrology, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York, USA; Department of Medicine, Mailman School of Public Health, Columbia University, New York, New York, USA.

Sundaram Hariharan (S)

Department of Medicine, Renal-Electrolyte Division, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH